Tardive Dyskinesia Clinical Trial
Official title:
Tardive Dyskinesia and Cognitive Function
Previous researchers indicate that impaired cognitive flexibility was the primary factor distinguishing patients with from those without tardive dyskinesia (TD)1, and cognitive dysfunction correlates positively with the severity of TD2. Longitudinal data raised the possibility that the association between cognitive dysfunction and TD may reflect not organic vulnerability to but rather a state marker for this movement disorder as "tardive dementia"3. Atypical antipsychotic had been reported to alleviate the severity of TD4 and improved neurocognitive function separately5. But no researchers ever investigated the correlation of the two effects simultaneously. This randomized, single-blind and controlled study compared the effect of atypical antipsychotic on TD, neurocognitive function and associated factors for these changes.
Eighty chronic schizophrenia inpatients who received conventional antipsychotics for more than one year, and met Schooler and Kane's criteria for persistent TD were enrolled in the study. The subjects were randomized to three groups: the olanzapine, amisulpride and FGA (first generation antipsychotic) controlled groups. Neurocognitive function were assessed using Wisconsin Card Sorting Test (WSCT) and Continuous Performance test (CPT) at baseline, 12th week and 24th week. Clinical successive ratings were performed with Brief psychiatric Rating Scale (BPRS), AIMS (Abnormal Involuntary Movement Rating Scale), Simpson-Angus Rating Scale (SAS), Udvalg for Kliniske Undersogelser side effect ratings (UKU) and Barnes akathesia scale (BAS).To evaluate the influences of prognostic factors on tardive dyskinesia and neurocognitive function and to control for all potential confounding variables, longitudinal analyses on the repeated measures data were conducted using generalized estimating equation models (GEE). ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02840760 -
Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.
|
N/A | |
Completed |
NCT01688037 -
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
|
Phase 2 | |
Completed |
NCT01391390 -
Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
|
N/A | |
Withdrawn |
NCT03254186 -
Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia
|
Phase 2/Phase 3 | |
Completed |
NCT02291861 -
Addressing Involuntary Movements in Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT02274558 -
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT02198794 -
Reducing Involuntary Movements in Participants With Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT01467089 -
The Assessment of Movement Disorders Utilizing Live Two-Way Video
|
N/A | |
Completed |
NCT04794413 -
Pimavanserin Treatment in TS
|
Early Phase 1 | |
Recruiting |
NCT06011408 -
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes
|
N/A | |
Recruiting |
NCT05859698 -
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
|
Phase 4 | |
Active, not recruiting |
NCT02252380 -
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
|
N/A | |
Terminated |
NCT00917293 -
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
|
Phase 2 | |
Completed |
NCT01543321 -
Xenazine in Late Dyskinetic Syndrome With Neuroleptics
|
Phase 3 | |
Completed |
NCT02405091 -
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT03176771 -
Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
|
Phase 2/Phase 3 | |
Terminated |
NCT02524886 -
Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia
|
N/A | |
Completed |
NCT02195700 -
Aim to Reduce Movements in Tardive Dyskinesia
|
Phase 2/Phase 3 | |
Completed |
NCT02736955 -
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
|
Phase 3 | |
Completed |
NCT03497013 -
Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia
|
N/A |